GTCR and Cole-Parmer’s Acquisition of ZeptoMetrix

Kirkland & Ellis advised Cole-Parmer on the deal.

GTCR, a leading private equity firm, announced that its Cole-Parmer (“CP”) portfolio company has acquired ZeptoMetrix Corporation (“ZeptoMetrix”). The acquisition expands CP’s quality controls and reference standards portfolio, and further establishes CP as a leading manufacturer of specialty chemistries and reagents for life sciences research and diagnostic testing.

ZeptoMetrix is a life sciences developer and manufacturer of quality control standards and verification panels used in molecular diagnostic testing for infectious diseases.

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Healthcare, Financial Services & Technology, Technology, Media & Telecommunications, and Growth Business Services industries.

Founded in 1955, Cole-Parmer® is a leading global manufacturer of proprietary products for fluidics, critical research and process equipment and specialty chemicals for life sciences, environmental sampling and analysis, analytics and essential lab supplies.

The Kirkland team was led by transactional partners Chris Thomas (Picture), Michael Weed and Sanford Perl, and associates Edward Brennan and Kate Vandenberg; tax partners Gregory Gallagher and Polina Liberman; and debt finance partners Jocelyn Hirsch and Carolyn Aiken.

Involved fees earner: Carolyn Aiken – Kirkland & Ellis; Edward Brennan – Kirkland & Ellis; Gregory Gallagher – Kirkland & Ellis; Jocelyn Hirsch – Kirkland & Ellis; Polina Liberman – Kirkland & Ellis; Sanford Perl – Kirkland & Ellis; Christopher Thomas – Kirkland & Ellis; Michael Weed – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: Cole-Parmer;


Author: Ambrogio Visconti